drugset / Trial / NCT03961100

A Performance and Bioavailability Study of Entrectinib in Healthy Volunteers.

NCT03961100

Phase 1 Completed 31 enrolled Genentech, Inc.
RandomizedCrossoverOpen-labelTreatment

Summary

This study will evaluate the bioavailability, palatability, safety and tolerability of entrectinib in healthy volunteers. Part 1 of the study will explore the performance of entrectinib multi-particle formulation. Part 2 will evaluate the effect of drug substance particle size on entrectinib bioavailability.

Timeline

Start
2019-06-06
Primary completion
2019-08-09
Completion
2019-08-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Entrectinib Small molecule 200 mg Oral
Subject Entrectinib Small molecule 600 mg Oral

Indications